All In Biotech

Free tool

FAERS Monitor: Teriparatide

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218771 or its brand name (Teriparatide, Teriparatide). Reports on generic versions are filed under their own applications.

Reports

7,158

Serious

4,980

70% of reports

Hospitalization

2,518

Death reported

406

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness525
  • nausea523
  • fall503
  • fatigue487
  • back pain474
  • arthralgia461
  • device malfunction451
  • product dose omission issue433
  • pain in extremity425
  • pain397
  • headache391
  • device operational issue360
  • malaise299
  • asthenia280
  • dyspnoea238

Reports by year received

View as table
YearReports
200410
200533
200616
200757
200840
200952
201044
201185
2012307
2013509
2014150
2015142
2016129
2017310
2018437
2019492
2020228
2021185
2022299
2023476
2024986
20251,380
2026791

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,001 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
device operational issueSignal360268.3241.487,612
device malfunctionSignal45119.017.37,637
back painSignal4746.05.51,990
fallSignal5034.44.11,360
product dose omission issueSignal4334.34.01,120
pain in extremitySignal4254.23.91,064
arthralgiaSignal4613.33.0734
dizzinessSignal5253.12.9760
astheniaSignal2802.22.0183
malaiseSignal2992.01.8152
nausea5231.91.8247
pain3971.91.7173
fatigue4871.81.7192
headache3911.81.7152
dyspnoea2381.21.111

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.